FB-825 is under clinical development by Oneness Biotech and currently in Phase I for Allergic Rhinitis. According to GlobalData, Phase I drugs for Allergic Rhinitis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FB-825’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

FB-825 overview

FB-825 is under development for the treatment of allergic asthma, atopic dermatitis, allergic rhinitis, food alleryg and hyperimmunoglobulin E syndrome. It is administered through intravenous route. FB-825 is a humanized monoclonal antibody that targets to the specific CemX domain and kills the membrane IgE positive B lymphocytes. It is administered by intravenous route.

Oneness Biotech overview

Oneness Biotech is a biopharmaceutical company. The company’s product pipeline comprises ON101 against diabetic foot ulcer, FB825 for atopic dermatitis, allergic asthma, FB704A against severe asthma, OB318 against cancer and FB918 against asthma. It offers products in the therapeutic areas of dermatology, immunology and infectious diseases. Oneness Biotech is headquartered in Taipei, Taiwan.

For a complete picture of FB-825’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.